Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
The current coronavirus disease 2019 (COVID-19) pandemic, which is due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 5.5 million casualties to date. Despite ...
Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results